[go: up one dir, main page]

AU2012371260A8 - Predicitive biomarker for cancer treatment with ADCC enhanced antibodies - Google Patents

Predicitive biomarker for cancer treatment with ADCC enhanced antibodies

Info

Publication number
AU2012371260A8
AU2012371260A8 AU2012371260A AU2012371260A AU2012371260A8 AU 2012371260 A8 AU2012371260 A8 AU 2012371260A8 AU 2012371260 A AU2012371260 A AU 2012371260A AU 2012371260 A AU2012371260 A AU 2012371260A AU 2012371260 A8 AU2012371260 A8 AU 2012371260A8
Authority
AU
Australia
Prior art keywords
predicitive
biomarker
cancer treatment
enhanced antibodies
adcc enhanced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2012371260A
Other versions
AU2012371260A1 (en
Inventor
Christian Gerdes
Claude GIMMI
Simon HOLLINGSWORTH
Luigi MANENTI
Ruediger Rueger
Pablo Umana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Glycart AG
Original Assignee
Roche Glycart AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Glycart AG filed Critical Roche Glycart AG
Publication of AU2012371260A1 publication Critical patent/AU2012371260A1/en
Publication of AU2012371260A8 publication Critical patent/AU2012371260A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention is directed to methods for identifying which patients diagnosed with cancer will most benefit from treatment with an anti-cancer therapy comprising an ADCC-enhanced antibody.
AU2012371260A 2012-03-02 2012-03-02 Predicitive biomarker for cancer treatment with ADCC enhanced antibodies Abandoned AU2012371260A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2012/053600 WO2013127465A1 (en) 2012-03-02 2012-03-02 Predicitive biomarker for cancer treatment with adcc enhanced antibodies

Publications (2)

Publication Number Publication Date
AU2012371260A1 AU2012371260A1 (en) 2014-07-10
AU2012371260A8 true AU2012371260A8 (en) 2014-09-18

Family

ID=45814493

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012371260A Abandoned AU2012371260A1 (en) 2012-03-02 2012-03-02 Predicitive biomarker for cancer treatment with ADCC enhanced antibodies

Country Status (8)

Country Link
JP (1) JP2015511702A (en)
KR (1) KR20140130455A (en)
AU (1) AU2012371260A1 (en)
BR (1) BR112014018374A8 (en)
CA (1) CA2860369A1 (en)
MX (1) MX2014010379A (en)
RU (1) RU2014138586A (en)
WO (1) WO2013127465A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
TWI693073B (en) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 Therapeutic agent for GPC3 target is the effective therapeutic agent for GPC3 target administered to patients
WO2014114595A1 (en) 2013-01-23 2014-07-31 Roche Glycart Ag Predictive biomarker for cancer treatment with adcc-enhanced antibodies
JP6827319B2 (en) * 2014-05-08 2021-02-10 中外製薬株式会社 GPC3 targeted therapies GPC3 targeted therapies administered to patients for whom therapy is effective
MA40764A (en) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENT INDUCING CYTOTOXICITY
US11376326B2 (en) 2015-07-01 2022-07-05 Chugai Seiyaku Kabushiki Kaisha GPC3-targeting therapeutic agent which is administered to patient for whom the GPC3-targeting therapeutic agent is effective

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP2919890B2 (en) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル Single domain ligand, receptor consisting of the ligand, method for producing the same, and use of the ligand and the receptor
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
LU91067I2 (en) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and immunochemical derivatives including immotoxins
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
FI941572L (en) 1991-10-07 1994-05-27 Oncologix Inc Combination and method of use of anti-erbB-2 monoclonal antibodies
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
EP1071700B1 (en) 1998-04-20 2010-02-17 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
WO2003011878A2 (en) 2001-08-03 2003-02-13 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
ES2543734T3 (en) 2003-01-22 2015-08-21 Roche Glycart Ag Fusion constructs and use thereof to produce antibodies with greater affinity for Fc receptor binding and effector function
DK1871805T3 (en) 2005-02-07 2019-12-02 Roche Glycart Ag ANTI-BINDING MOLECULES BINDING EGFR, VECTORS CODING THEREOF, AND APPLICATIONS THEREOF
AR062223A1 (en) 2006-08-09 2008-10-22 Glycart Biotechnology Ag MOLECULES OF ADHESION TO THE ANTIGEN THAT ADHER TO EGFR, VECTORS THAT CODE THEM, AND THEIR USES OF THESE
DE602007013068D1 (en) * 2006-09-13 2011-04-21 Glycode METHOD FOR EXAMINING THE RESPONSE TO TREATMENT WITH A MONOCLONAL ANTIBODY
US20100247484A1 (en) * 2009-03-31 2010-09-30 Heinrich Barchet Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
US20120258076A1 (en) * 2009-12-16 2012-10-11 Hitachi Chemical Research Center, Inc. Method for characterizing host immune funtion by ex vivo induction of offensive and defensive immune markers

Also Published As

Publication number Publication date
AU2012371260A1 (en) 2014-07-10
CA2860369A1 (en) 2013-09-06
WO2013127465A1 (en) 2013-09-06
MX2014010379A (en) 2015-05-15
RU2014138586A (en) 2016-04-20
BR112014018374A2 (en) 2017-06-20
BR112014018374A8 (en) 2017-07-11
KR20140130455A (en) 2014-11-10
JP2015511702A (en) 2015-04-20

Similar Documents

Publication Publication Date Title
MX2015012122A (en) Antibody drug conjugates and corresponding antibodies.
TN2015000396A1 (en) Antibody drug conjugates
AU2011338480A8 (en) Humanized antibodies to LIV-1 and use of same to treat cancer
MX370818B (en) Anti-b7-h1 antibodies for treating tumors.
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
NZ702748A (en) Cd33 antibodies and use of same to treat cancer
GEP20217331B (en) Anti-tigit antibodies
MX360141B (en) Antibodies to integrin avb6 and use of same to treat cancer.
PH12015501071A1 (en) Combination therapy of anti-her3 antibodies
HK1199290A1 (en) Methods and compositions for the treatment and diagnosis of breast cancer
IN2014DN05885A (en)
EP4321866A3 (en) Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
PH12014501543A1 (en) Combination therapy for the treatment of ovarian cancer
MX2017000840A (en) Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer.
IN2014DN09717A (en)
AU2012371260A8 (en) Predicitive biomarker for cancer treatment with ADCC enhanced antibodies
MX347463B (en) Combination therapy of an afucosylated cd20 antibody with an anti-vegf antibody.
MX350807B (en) Compositions and methods for prostate cancer analysis.
WO2013052108A3 (en) Methods and compositions for the treatment and diagnosis of ovarian cancer
MX362497B (en) Methods for treatment of gastric cancer.
PH12014502461A1 (en) Biomarkers for iap inhibitor therapy
WO2013040358A3 (en) Assays and compositions for detection of agr2
WO2012106473A3 (en) Dosing for treatment with anti-egfl7 antibodies
IN2014CN02496A (en)

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 28 , NO 27 , PAGE(S) 3655 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME ROCHE GLYCART AG, APPLICATION NO. 2012371260, UNDER INID (71) CORRECT THE APPLICANT NAME TO ROCHE GLYCART AG

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application